Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05671510
Title	ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)
Acronym	PRESERVE-003
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	OncoC4, Inc.
Indications	lung non-small cell carcinoma
Therapies	ONC-392 Docetaxel
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS